PARP Inhibitor Niraparib: Oral Tablet Formulation for Ovarian Cancer
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
Convenient New Tablet Formulation
- June 9, 2022
Takeda Pharmaceutical announced Japanese regulatory approval of niraparib oral tablet 100mg formulation for ovarian cancer patients. The approval was based on bioequivalence and dissolution studies confirming equivalence between the new tablet and existing capsule formulations.
Approved Indications
Niraparib is approved for:
- First-line maintenance therapy after initial chemotherapy in ovarian cancer
- Maintenance therapy in platinum-sensitive recurrent ovarian cancer
- Treatment of platinum-sensitive recurrent ovarian cancer with homologous recombination repair deficiency
Key Advantage Over Capsule
The niraparib capsule formulation requires refrigerated storage. The new oral tablet formulation can be stored at room temperature, improving convenience and patient compliance, particularly in resource-limited settings or during extended travel.
Clinical Significance
Since Japanese launch of niraparib capsules in 2020, Takeda reports extensive clinical experience managing treatment of newly diagnosed and recurrent ovarian cancer patients. The tablet formulation expands access and improves practical management of maintenance therapy.
Data Source
https://www.takeda.com/ja-jp/announcements/2022/ZEJULA/
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.